Direct Oral Anticoagulants Exhibit Lower Risks of Mortality and Bleeding Compared to Vitamin K Antagonists in Atrial Fibrillation Patients on Chronic Hemodialysis: A Systematic Review and Meta-Analysis.

In 30 seconds

This systematic review and meta-analysis compared direct oral anticoagulants (DOACs) with vitamin K antagonists in patients with atrial fibrillation receiving chronic hemodialysis. Nine studies were included. DOAC use was associated with lower risks of all-cause stroke, ischemic stroke, all-cause mortality, major bleeding, gastrointestinal bleeding, and intracranial hemorrhage. The largest reported reduction among these outcomes was for ischemic stroke (RR 0.53; 95% CI: 0.29-0.96; P = 0.04). Cardiovascular-related death, clinically relevant nonmajor bleeding, and hemorrhagic stroke did not differ significantly between groups.

Key findings

• All-cause stroke was lower with DOACs than vitamin K antagonists (RR: 0.64; 95% CI: 0.51-0.81; P = 0.0001; I2 = 0%).
• All-cause mortality was lower with DOACs (RR: 0.73; 95% CI: 0.60-0.88; P = 0.001; I2 = 71%).
• Major bleeding was lower with DOACs (RR: 0.63; 95% CI: 0.52-0.76; P < 0.00001; I2 = 44%).
• No significant differences were found for cardiovascular-related death, clinically relevant nonmajor bleeding, or hemorrhagic stroke.

Why it matters

Anticoagulation decisions in atrial fibrillation during chronic hemodialysis involve balancing thromboembolic and bleeding outcomes. This pooled evidence reports lower risks across several stroke and bleeding outcomes with DOACs compared with vitamin K antagonists, while also identifying outcomes without significant differences. The findings help frame the comparative evidence but do not establish that DOACs cause these differences.

What to keep in mind

The analysis included nine studies, and heterogeneity was substantial for all-cause mortality (I2 = 71%). The abstract does not specify study designs or provide further detail on the included populations.